Mymetics Corp (MYMX)

[Work Harder]

This study at HZI will evaluate the safety and immunogenicity of different virosome-based Covid-19 vaccine candidates by intramuscular and intranasal administrations. The virosome formulations will incorporate and evaluate two different SARS-CoV-2 antigens, one full length stabilized S protein, for which Mymetics is collaborating with the group of Dr. Rogier Sanders at the Amsterdam Medical Center of the University of Amsterdam, the Netherlands, and the second is a receptor binding domain recombinant protein of SARS-CoV-2.

The study at HZI is part of the TRANSVAC2 services, funded by the European Union's Horizon 2020 research and innovation program under grant agreement N° 730964, to which Mymetics' subsidiary Mymetics SA in Switzerland received access to in June this year, results are expected in January 2021.

https://www.biospace.com/article/releases/mymetics-corporation-update/

Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection

2021 Mar 4

Published: January 26, 2021

project administration, and funding acquisition, R.L.G. and R.W.S.

Amsterdam UMC has filed a patent application concerning the SARS-CoV-2 mAbs used here (Brouwer et al., 2020)

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834972/

Application filed by Progenics Pharmaceuticals, Inc., Cornell Research Foundation, Inc.

https://patents.google.com/patent/WO2003022869A2/en

https://vivo.weill.cornell.edu/display/cwid-rws2002